摘要
目的:探讨采用不同剂量阿托伐他汀和瑞舒伐他汀治疗急性冠状动脉综合征患者的临床效果。方法:按照治疗方案不同将135例急性冠状动脉综合征患者进行分组,瑞舒伐他汀组45例(10mg瑞舒伐他汀)、阿托伐他汀A组45例(10mg阿托伐他汀)和阿托伐他汀B组45例(20mg阿托伐他汀),对比三组治疗前、后血脂水平及炎症因子变化。结果:瑞舒伐他汀组、阿托伐他汀B组患者的PAI-1、MMP-9、TC、LDL-C的降低幅度均明显优于阿托伐他汀A组,P<0.05;瑞舒伐他汀组患者血清炎症因子和血脂水平变化之间无明显相关性。结论:采用瑞舒伐他汀和阿托伐他汀治疗ACS均能够有效促使血清炎症因子水平下降,且其效果同药物剂量有关。
Objective：To investigate the effects of different dose of atorvastatin and rosuvastatin treatment comprehensive clinical effect in patients with acute coronary syndrome.Methods：According to the different treatment 135 cases of acute coronary syndrome patients were grouped,rosuvastatin group 45cases（10mg rosuvastatin）,atorvastatin group A 45cases（10mg atorvastatin）and atorvastatin group B 45cases（20mg atorvastatin）,the changes of blood lipid the inflammatory factor and compared before and after treatment in three groups.Results：Rosuvastatin,atorvastatin group B in patients with PAI-1,MMP-9,TC,LDL-C decreased significantly better than atorvastatin group A,P0.05;rosuvastatin no significant correlation between the changes of serum levels of inflammatory factors in the atorvastatin group and blood lipid level.Conclusion：The use of rosuvastatin and atorvastatin treatment ACS can effectively make inflammation factors level in serum decreased,and the decreased effect of drug related with measurement.
出处
《医学理论与实践》
2015年第6期712-713,共2页
The Journal of Medical Theory and Practice
